Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

The dopamine hypothesis posits that anomalies in dopamine receptors contribute to schizophrenia symptoms. Excessive dopaminergic neurotransmission in the brain results from these receptor irregularities. Dopamine D2 antagonists like chlorpromazine and haloperidol block postsynaptic dopamine receptors, effectively treating the disorder by reducing this overactivity.

The serotonin hypothesis suggests that imbalances in serotonin levels are involved in schizophrenia pathogenesis. Second-generation antipsychotics antagonize the 5HT2A receptor, offering unique clinical features and binding profiles. This approach provides a broader spectrum of treatment options beyond dopamine-targeting medications for managing psychotic symptoms.

The glutamate hypothesis links dysfunction in glutamate neurotransmission, particularly NMDA receptor hypofunction, to schizophrenia manifestations. Reduced NMDA receptor function diminishes activity in mesocortical dopaminergic neurons. Understanding altered glutamate transmission may help develop improved antipsychotic drugs that enhance AMPA-type glutamate currents.

Schizophrenia is characterized by complex genetics and incompletely understood pathophysiology rooted in neurodevelopment. Various genetic components have been identified as risk factors, underscoring the intricate interplay between genetic and environmental factors in disease development. This genetic foundation distinguishes it as a neurodevelopmental rather than purely acquired disorder.

First-generation antipsychotics like chlorpromazine and haloperidol block postsynaptic dopamine D2 receptors to treat schizophrenia. Newer agents enhance AMPA-type glutamate currents to rectify psychotic behavior without exhibiting neurotoxicity. This represents a shift from dopamine-only targeting to multi-system approaches addressing glutamate dysfunction.

Anomalies in dopamine receptors are central to schizophrenia pathophysiology, with excessive dopaminergic neurotransmission in the brain and periphery contributing to symptom manifestation. Blocking postsynaptic dopamine receptors with antagonists effectively mitigates these symptoms. This receptor-based mechanism forms the foundation for dopamine-targeting antipsychotic drug development.

Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring complex genetic components in disease origins. These genetic risk factors interact with environmental influences in disease development. Despite burgeoning understanding, the complete pathophysiology remains incompletely deciphered, highlighting ongoing research needs.